Chapter 1. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– By Cancer Type

6.1. Clear cell RCC

6.2. Papillary RCC

6.3. Chromophobe RCC

6.4. Urothelial carcinoma/Transitional cell carcinoma

6.5. Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)

Chapter 7. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– By Component

7.1. Drugs

       7.1.1. Therapeutic Class

              7.1.1.1. Targeted Therapy

              7.1.1.2. Immunotherapy

              7.1.1.3. Other Therapeutic Class

       7.1.2. Pharmacologic Class

              7.1.2.1. Angiogenesis Inhibitors

              7.1.2.2. Monoclonal Antibodies

              7.1.2.3. mTOR Inhibitors

              7.1.2.4. Cytokine Immunotherapy (IL-2)

7.2. Diagnostics

       7.2.1. Biopsy

       7.2.2. Imaging Tests

       7.2.3. Blood Tests

       7.2.4. Other Diagnostics

Chapter 8. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET– By Region

8.1. North America

8.2. Europe

8.3. The Asia Pacific

8.4. Latin America

8.5. Middle-East and Africa

Chapter 9. KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Company 1

9.2. Company 2

9.3. Company 3

9.4. Company 4

9.5. Company 5

9.6. Company 6

9.7. Company 7

9.8. Company 8

9.9. Company 9

9.10. Company 10